

SICKLE CELL DISEASE

Affordable Design and Entrepreneurship | Global Health Fall 2015

Pinar Demetci | Hayley Hansson
Celine Ta | Anne Wilkinson
Advisor: Anna Konstantinova

Sickle cell disease (SCD) is an inherited condition that causes production of abnormal hemoglobin. This leads to **painful, and often fatal, complications**, including swelling, anemia, and a weakened immune system.

SCD is **most common** among populations in **Sub-Saharan Africa**.

Normal red blood cell



Sickled cell




185,600/yr

die before age 5 due to SCD in sub-Saharan Africa

8.3 million

possible lives saved with universal screening in sub-Saharan Africa by 2050



Expensive, slow diagnostics are the barrier to existing low-cost care.

Current Diagnostics: 2.5 - 15 USD/test
Equipment cost: 250 - 1050 USD
Turnaround: 30 min - 1 month

Low-cost Care:
free workshops on preventing sickle crisis
routine screenings & vaccinations

Patients

Families affected by SCD are not aware of the disease and how to manage the condition on a day-to-day basis.


Clinics

Without a diagnosis, providing patients appropriate treatment takes longer.

Ministries of Health

Data regarding sickle cell disease prevalence has not been officially updated in 20 years.

Stakeholder Considerations



time = lost income (travel time, etc.)



limited time and training



large scale demands cost-effectiveness



varied insurance coverage



limited equipment, materials; grid failure

Our Mission

Together with our partner Daktari Diagnostics, we aim to **make low-cost, point-of-care sickle cell diagnostics available to everyone.**


DAKTARI SICKLE CELL TEST

Affordable Design and Entrepreneurship | Global Health Fall 2015

Pinar Demetci | Hayley Hansson
Celine Ta | Anne Wilkinson

ADE Advisor: Anna Konstantinova
Daktari Liaison: Aaron Oppenheimer

Product Introduction



Two-phase solutions separate regular red blood cells from denser sickled cells in a blood sample when spun in a centrifuge. Our team is automating the imaging system for easier, more consistent diagnoses.


Deployment is planned for late 2017.

Time: 10 minutes


Sensitivity: >95%, **Specificity:** >97%
(n=1500)

Cost: <\$1.50 per test

Rechargeable battery



Imaging Prototype




Future Work

PROTOTYPE

Differentiate samples based on the reading scale (right), in order to give a more accurate diagnosis.

USER EXPERIENCE

Design and test user experience in the field.



SOCIAL RETURN ON INVESTMENT

Refined numerical evaluation of sickle cell diagnostics' impacts.